Virta, a telehealth startup that helps people manage diabetes with frequent monitoring and dietary counseling, raises $133M Series E, valuing the startup at $2B
Katie Jennings / Forbes : Thanks: @thealexknapp
Context & Ripple Effects
This round closes a strikingly fast gap in Virta's own funding arc: barely four months after a $65M raise that valued the company around $1.1B, investors put in another $133M at a $2B valuation — near-doubling its price tag in under five months without an intervening product pivot.
The raise also extends a pattern across chronic-care telehealth: Livongo's $105M Series E back in 2018 set the template at a sub-$1B valuation, while Cadence's $100M virtual-monitoring round in late 2021 showed capital flowing to adjacent remote-patient-monitoring plays, and Oviva has been pursuing the same Type 2 diabetes treatment model from Europe.
First-order effects
- Virta now holds one of the largest war chests among diabetes-focused telehealth startups, letting it scale frequent-monitoring and dietary-counseling programs ahead of rivals still raising smaller rounds.
Second-order effects
- Competitors like Oviva in Europe and device-plus-app players such as Livongo face pressure to match Virta's capital intensity, since payers evaluating digital diabetes programs increasingly compare funded, scaled vendors rather than pilots.
Third-order effects
- If valuations keep climbing faster than rounds can be spaced apart, chronic-disease management consolidates into a handful of heavily capitalized platforms, raising the bar for new entrants to prove clinical outcomes before attracting late-stage money.
The trend: Venture capital is concentrating on chronic-condition telehealth platforms, with diabetes care companies' valuations escalating round over round as remote monitoring moves from pilot programs to payer-scale offerings.